Recently, the 11th Sino-French Hematology Academic Conference, organized by the Chinese Medical Doctor Association, was successfully held in Tianjin, attracting hundreds of top experts and scholars in the field of hematology from China and abroad. During the conference, Dr. Frédéric Millot from the University Hospital of Poitiers, France, was invited by "Hematology Frontier" to share the future directions in the treatment of chronic myeloid leukemia (CML) in children.

Oncology Frontier-Hematology Frontier：In 2024, what major changes or innovations do you anticipate in the treatment of childhood chronic myeloid leukemia (CML)?

Dr. Frédéric Millot ：I think we will have some changes with the advent of new drugs, and we are waiting for the two prospective trials with two drugs. One with a third generation TKI and another drug in development is Asciminib.

Oncology Frontier-Hematology Frontier：With the rapid advancement of gene editing technologies , what role do you envision these technologies playing in the personalized treatment of childhood CML in the coming years?

Dr. Frédéric Millot ：I think it’s a very important point. This can help, this such analysis can help in order to identify a patient with risk of resistance of the disease by the future. It will be a very important .. Currently, such analysis are not included in the algorithm of treatment, but maybe within a few years, it will be an important part regarding the chronic stick of the disease.

Oncology Frontier-Hematology Frontier：How do you anticipate the area for childhood CML will evolve beyond 2024, and what are the key factors driving these changes?

Dr. Frédéric Millot ：I think one of the most important thing is to try to set up a prognostic score specific to the patient population. This will be very important in order, again, to try to identify a patient with high risk of resistance of the disease. This is a very important point, I think. And we are working in the international registry regarding this specific score and we hope to succeed within a few months or years.